Literature DB >> 6328334

UD-CG 115--a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle.

P Honerjäger, A Heiss, M Schäfer-Korting, G Schönsteiner, M Reiter.   

Abstract

The mechanism of the positive inotropic effect of a benzimidazole-pyridazinone, UD-CG 115, was analysed in the isolated guinea-pig papillary muscle contracting isometrically at a frequency of 0.2 Hz. UD-CG 115 produced a slowly developing and poorly reversible positive inotropic effect increasing with concentration (3-300 mumol/l). The effect amounted to 30 and 74% of the maximum inotropic effect of a standard, dihydroouabain, at 34 and 300 mumol/l, respectively. Low concentrations shortened and 300 mumol/l UD-CG 115 significantly prolonged the duration of contraction. The enhancement of the maximum rate of relaxation, S2, was intermediate between those produced by isoprenaline and dihydroouabain, respectively. UD-CG 115 prolonged the duration of the transmembrane action potential (90% repol .) by up to 22% at 300 mumol/l, whereas an equieffective concentration of isoprenaline did not consistently alter action potential duration. UD-CG 115 increased Vmax and overshoot, and prolonged the duration, of slow action potentials elicited at 24 mmol/l [K]0. The inotropic potency of UD-CG 115 was not significantly changed by reserpine pretreatment of the guinea pig or by the presence of 1 mumol/l(-)-propranolol, 3 mumol/l phentolamine or 10 mumol/l cimetidine. Neither was it reduced by 10 mumol/l TTX. The inotropic effect of 100 mumol/l UD-CG 115 remained unchanged when [K]0 was elevated from 3.2 to 12.0 mmol/l. A sarcolemmal preparation of guinea- pig ventricular Na,K-ATPase was only slightly inhibited by the highest concentration of UD-CG 115.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328334     DOI: 10.1007/bf00495953

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  [Electrophysiological measurement of strophanthin effects on heart muscle].

Authors:  J DUDEL; W TRAUTWEIN
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1958

2.  Effects of several phosphodiesterase-inhibitors on guinea-pig myocardium.

Authors:  M Korth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-03       Impact factor: 3.000

Review 3.  Cyclic AMP and contractile activity in heart.

Authors:  R W Tsien
Journal:  Adv Cyclic Nucleotide Res       Date:  1977

Review 4.  Properties of two inward membrane currents in the heart.

Authors:  H Reuter
Journal:  Annu Rev Physiol       Date:  1979       Impact factor: 19.318

5.  "Supramaximal" enhancement of the inotropic effect of noradrenaline by tyramine.

Authors:  W Brandt; M Reiter; K Seibel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

Review 6.  Strategy for the discovery and development of a positive inotropic agent.

Authors:  D B Evans; R E Weishaar; H R Kaplan
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

7.  The effects of p-chloromercuriphenylsulfonic acid (PCMBS) on force of contraction of mammalian myocardium and on ATP hydrolysis by sarcolemmal ATPase.

Authors:  S Halbach; G Schönsteiner; F Ebner; M Reiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-12       Impact factor: 3.000

8.  The effects of adrenaline and theophylline on action potential and contraction of mammalian ventricular muscle under "rested-state" and "steady-state" stimulation.

Authors:  A Beresewicz; H Reuter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-12       Impact factor: 3.000

9.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.

Authors:  M Endoh; S Yamashita; N Taira
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

10.  On the ionic mechanism underlying adrenergic-cholinergic antagonism in ventricular muscle.

Authors:  I Josephson; N Sperelakis
Journal:  J Gen Physiol       Date:  1982-01       Impact factor: 4.086

View more
  15 in total

1.  Fluorescence Based Characterization of Calcium Sensitizer Action on the Troponin Complex.

Authors:  William Schlecht; King-Lun Li; Dehong Hu; Wenji Dong
Journal:  Chem Biol Drug Des       Date:  2015-09-16       Impact factor: 2.817

2.  Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle.

Authors:  M Galvan; C Schudt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

3.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

4.  Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside.

Authors:  G Hasenfuss; C Holubarsch; H W Heiss; B Rattert; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 5.  Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.

Authors:  H von der Leyen
Journal:  Klin Wochenschr       Date:  1989-06-15

Review 6.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

7.  Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212.

Authors:  S T Rapundalo; D A Lathrop; S A Harrison; J A Beavo; A Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

8.  Systemic haemodynamic actions of pimobendan (UD-CG 115 BS) and its O-demethylmetabolite UD-CG 212 Cl in the conscious pig.

Authors:  D J Duncker; J M Hartog; L Levinsky; P D Verdouw
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

9.  Positive inotropic effects of the calcium channel activator Bay K 8644 on guinea-pig and human isolated myocardium.

Authors:  M Näbauer; L Brown; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

10.  DPI 201-106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory properties.

Authors:  G Scholtysik; R Salzmann; R Berthold; J W Herzig; U Quast; R Markstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.